Etude de marché sur les Biomarqueurs-Définition des critères des industriels pour le développement d'un biomarqueur ,
Les révolutions de la recherche sur le cancer. Fondation ARC pour la recherche sur le cancer ,
Pharmacogénomique des anticancéreux. Exemples de la Bléomycine et du ,
Sciences du Vivant, 2010. ,
Hallmarks of Cancer: The Next Generation, vol.144, pp.646-674, 2011. ,
Découverte de biomarqueurs prédictifs en cancer du sein par Intégration Transcriptome-Interactome. Aix-Marseille Université, 2013. ,
Detection of single nucleotide polymorphisms by PCR conformation-difference gel electrophoresis, J. of Biotech. Let, vol.35, pp.515-522, 2012. ,
Initiative for Molecular Profiling and Advanced Cancer Therapy and Challenges in Implementation of Precision Medicine. Personalized Medicine in a Phase 1 Clinical Trials Program, Current Problems in Cancer ,
,
, Guide ESMO à l'usage des patients. ESMO Médecine personnalisée
La médecine personnalisée appliquée à l'efficacité et à la sécurité des médicaments, vol.17 ,
Médecine de précision : Concrétiser la vision des résultats personnalisés en santé. Un modèle de médecine de précision ,
, Plan cancer, 2014.
, Quatrième rapport au président de la république, 2018.
Defining precision : The precision medicine initiative TRIALS NCI-MPACT and NCI-MATCH. Current Problems in Cancer ,
,
Basket Cases: Changing the Way Cancer Is Treated. Cure. 15 avril, 2016. ,
A New Initiative on Precision Medicine, N Engl J Med, vol.372, issue.9, pp.793-798, 2015. ,
DOI : 10.1056/nejmp1500523
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5101938/pdf
La médecine personnalisée, espoir de lutte contre le cancer. Note de presse, 2012. ,
Les nouveaux enjeux éthiques de la médecine prédictive et personnalisée, 2012. ,
« Le patient « actionnable » de la médecine personnalisée, vol.29, pp.37-51, 2014. ,
Bienvenue dans l'ère de la médecine personnalisée, 1921. ,
Recherche translationnelle : médecine personnalisée, médecine de précision, thérapies ciblées : marketing ou science ? Thérapie, Janvier-Février, vol.70, issue.1, pp.1-10, 2015. ,
Tumor cell resistance against targeted therapeutics: the density of cultured glioma tumor cells enhances Stat3 activity and offers protection against the tyrosine kinase inhibitor canertinib, Med. Chem. Commun, vol.8, pp.96-102, 2017. ,
The clonal evolution of tumor cell populations, Science, vol.194, pp.23-31, 1976. ,
Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy, Genome Med, vol.9, p.37, 2017. ,
Tumour heterogeneity and the evolution of polyclonal drug resistance ,
, Mol Oncol, vol.8, issue.6, pp.1095-111, 2014.
Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis, International Journal of Molecular Sciences, vol.17, pp.2142-2142, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01466086
,
Circulating tumor cells in breast cancer: functional heterogeneity, pathogenetic and clinical aspects, Experimental Oncology, vol.39, issue.1 ,
Evaluation and consequences of heterogeneity in the circulating tumor cell compartment, Oncotarget, vol.7, pp.48625-48643, 2016. ,
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future, Cell, vol.168, pp.613-628, 2017. ,
Translational Implications of Tumor Heterogeneity, Clin Cancer Res, vol.21, issue.6, 2015. ,
Tumor heterogeneity: a central foe in the war on cancer The JCSO, vol.16, pp.167-174, 2018. ,
Tumor Evolution as a Therapeutic Target, 2017. ,
Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution, Scientific Reports, vol.7, p.44206, 2017. ,
High-sensitivity assay for monitoring ESR1 mutations in circulating cellfree DNA of breast cancer patients receiving endocrine therapy, Sci Rep, vol.8, p.4371, 2018. ,
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine, Br J Cancer, vol.103, issue.8, pp.1139-1143, 2010. ,
Clonal evolution and heterogeneity of cancer in the context of individualized medicine, 2018. ,
Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine, Drug Discovery Today, vol.22, issue.8, pp.1148-1164, 2017. ,
Somatic Mutation Detection in Leukemia-Derived Circulating DNA: Utility in ,
, Monitoring Clonal Dynamics and Disease Response in Pediatric Acute Lymphoblastic Leukemia, Theses and Dissertations, 2018.
Single-cell sequencing and tumorigenesis: improved understanding of tumor evolution and metastasis, Clin Transl Med, vol.6, issue.1, p.15, 2017. ,
Cellular Heterogeneity and Molecular Evolution in Cancer, Annual Review of Pathology: Mechanisms of Disease, vol.8, issue.1, pp.277-302, 2013. ,
The promise of circulating tumor cells for precision cancer therapy Biomark Med, vol.10, pp.1269-1285, 2016. ,
A conduit to metastasis: circulating tumor cell biology, Genes Dev ,
, Sep, vol.15, issue.18, pp.1827-1840
The Landscape of Circulating Tumor Cell Research in the Context of Epithelial-Mesenchymal Transition, Pathobiology, vol.84, pp.264-283, 2017. ,
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer, JCO Precis Oncol, 2018. ,
Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker, Oncotarget, vol.8, issue.43, pp.75742-75755, 2017. ,
The application of estrogen receptor-1 mutations' detection through circulating tumor dna in breast cancer, Cancer Transl Med, vol.3, pp.46-52, 2017. ,
Genetic Heterogeneity and Clonal Evolution of Tumor Cells and their Impact on Precision Cancer Medicine, J Leuk (Los Angel), vol.1, p.124, 2013. ,
Integrating liquid biopsies into the management of cancer, Nat Rev Clin Oncol, vol.14, issue.9, pp.531-548, 2017. ,
Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies, Cancer Research, vol.78, issue.8, pp.2127-2139, 2018. ,
, , 2016.
, , vol.97, pp.178-196
The value of cell-free DNA for molecular pathology, J Pathol, 2018. ,
, , vol.244, pp.616-627, 2018.
Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers, Pathobiology, vol.85, issue.1-2, pp.146-154, 2017. ,
Circulating tumor cells in genitourinary tumors, Ther Adv Urol, 2018. ,
Circulating tumor cells capture disease evolution in advanced prostate cancer, Journal of Translational Medicine201715, p.44 ,
Non-invasive diagnostic platforms in management of nonsmall cell lung cancer: opportunities and challenges, vol.5, 2017. ,
Clonal origin and spread of metastatic prostate cancer, Endocr Relat Cancer, vol.23, issue.4, pp.207-217, 2016. ,
Les acides nucléiques du plasma sanguin chez l'homme ,
, Seances Soc. Biol. Fil, vol.142, pp.241-243, 1948.
Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res, vol.37, pp.646-650, 1977. ,
Neoplastic characteristics of the DNA found in the plasma of cancer patients, Oncology, vol.46, pp.318-322, 1989. ,
Soluble normal and mutated DNA sequences from single-copy genes in human blood, Cancer Epidemiol Biomarkers Prev, 1994. ,
Clonal evolution in hematological malignancies and therapeutic implications, Leukemia, vol.28, issue.1, pp.34-43, 2014. ,
Circulating nucleic acids (CNAs) and cancer-a survey, Biochim Biophys Acta, vol.1775, issue.1, pp.181-232, 2007. ,
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA, Nature, vol.497, pp.108-112, 2013. ,
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, vol.486, pp.532-536, 2012. ,
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers, Nature, vol.486, pp.537-540, 2012. ,
Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology, Ther Adv Med Oncol, vol.10, p.1758835918794630, 2018. ,
Personalized therapy for lung cancer: Striking a moving target, JCI Insight ,
, Aug, vol.9, issue.15
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer, Nat Commun, vol.6, p.8760, 2015. ,
Detection and localization of surgically resectable cancers with a multianalyte blood test, Science, vol.359, issue.6378, pp.926-930, 2018. ,
Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers, Sci Transl Med, vol.5, issue.167, pp.167-171, 2009. ,
Analysis of circulating tumor DNA to monitor metastatic breast cancer ,
, N Engl J Med, vol.368, issue.13, pp.1199-209, 2013.
Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts, Nucleic Acids Res, vol.38, issue.18, pp.6159-75, 2010. ,
Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, issue.224, pp.224-248, 2014. ,
Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma, Cancer Biol Ther, vol.5, issue.10, pp.1369-74, 2006. ,
Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis, Int J Cancer, vol.100, issue.5, pp.542-550, 2002. ,
Quantification of free circulating DNA as a diagnostic marker in lung cancer, J Clin Oncol, vol.21, issue.21, pp.3902-3910, 2003. ,
Liquid biopsy: monitoring cancergenetics in the blood, Nat Rev Clin Oncol, vol.10, pp.472-84, 2013. ,
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood, Clin Cancer Res, vol.18, issue.12, pp.3462-3471, 2012. ,
Circulating tumour DNA analysis in multiple myeloma ,
, Oncotarget, vol.8, issue.53, pp.90610-90611, 2017.
Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types ,
, Mol. Oncol, vol.9, pp.783-790, 2015.
Exome sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease, PLoS One, vol.10, p.136407, 2015. ,
Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies, Pharmacol Ther, vol.157, pp.120-124, 2016. ,
Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer, Ann Oncol, vol.27, pp.862-869, 2016. ,
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution, Nature, vol.545, pp.446-51, 2017. ,
Tracking the evolution of non-small-cell lung cancer, N Engl J Med, vol.376, pp.2109-2130, 2017. ,
Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance, Sci Rep, vol.6, issue.1, p.20913, 2016. ,
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for antiEGFR treatment, Ann Oncol, vol.28, issue.9, pp.2149-2159, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01682168
Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC), J Clin Oncol, vol.35, p.9025, 2017. ,
Utility of genomic assessment of bloodderived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma ,
, Clin Cancer Res, vol.23, pp.5101-5112, 2017.
Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis, Cancer Epidemiol Biomarkers Prev, vol.24, pp.206-218, 2015. ,
Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer, Sci. Rep, vol.5, p.18425, 2015. ,
Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients, Oncotarget, vol.7, issue.22, pp.32504-32522, 2016. ,
Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients, Breast Cancer Res Treat, vol.155, issue.1, pp.139-188, 2016. ,
Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer, Oncotarget, vol.8, pp.12501-12516, 2017. ,
Extracellular tumor DNA in plasma and overall survival in breast cancer patients, Genes Chromosomes Cancer, vol.31, pp.692-701, 2006. ,
Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA, J Natl Cancer Inst, vol.92, pp.918-923, 2000. ,
A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis, Pancreas, vol.25, pp.336-341, 2002. ,
K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance, J Clin Oncol, vol.17, pp.578-584, 1999. ,
Detection of mutations in EGFR in circulating lung-cancer cells ,
, N Engl J Med, vol.359, pp.366-377, 2008.
Detection of circulating tumor cells in men with localized prostate cancer, J Clin Oncol, vol.12, pp.2634-2639, 1994. ,
Early TKI-pharmokinetics and circulating tumor DNA (ctDNA) to predict outcome in patients with EGFR-mutated non-small cell lung cancer (NSCLC), J Clin Oncol, vol.35, p.11544, 2017. ,
Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.99, issue.2, pp.20-21, 2017. ,
Reproducibility of a semiquantitative measurement of circulating DNA in plasma from neoplastic patients, J Clin Oncol, vol.23, pp.3163-3164, 2005. ,
Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients, Gastroenterology, vol.135, pp.489-498, 2008. ,
A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant nonsmall cell lung cancer patients treated with erlotinib on a phase II trial, Clin Cancer Res, vol.22, issue.24, pp.6010-6030, 2016. ,
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients, Nat. Commun, vol.6, p.7686, 2015. ,
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing, Genome Med, vol.5, p.90, 2013. ,
Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA, Oncotarget, vol.4, pp.1856-1857, 2013. ,
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann. Oncol, vol.26, pp.1715-1722, 2015. ,
Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration, Clin. Cancer Res, vol.21, pp.4586-4596, 2015. ,
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA, Clin Cancer Res, vol.20, issue.6, pp.1698-705, 2014. ,
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer, Sci Transl Med, vol.7, pp.302-133, 2015. ,
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer, Sci Transl Med, vol.7, pp.302-133, 2015. ,
Molecular analysis of circulating tumour cells-biology and biomarkers, Nat. Rev. Clin. Oncol, vol.11, pp.129-144, 2014. ,
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery, Gut, vol.65, pp.625-634, 2015. ,
Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection ,
, Ann. Surg. Treat. Res, vol.86, pp.136-142, 2014.
Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies, Journal of Clinical Oncology, vol.35, pp.15-8519, 2017. ,
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer, Sci Transl Med, vol.8, pp.346-92, 2016. ,
Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma, Leukemia, vol.31, issue.8, pp.1695-1705, 2017. ,
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients ,
, Nat Med, vol.21, issue.7, pp.795-801, 2015.
AZD9291 in EGFR inhibitor-resistant non-smallcell lung cancer, N Engl J Med, vol.372, pp.1689-99, 2015. ,
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients, Nat Commun, vol.7, p.11815, 2016. ,
Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial, JAMA Oncol, vol.1, pp.149-157, 2015. ,
Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the singlepoint substitution mutation L858R in non-small cell lung cancer, Oncotarget, vol.7, pp.29154-29165, 2016. ,
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat Med, vol.21, pp.560-562, 2015. ,
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs, JAMA, vol.311, pp.1998-2006, 2014. ,
Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer, J. Clin. Oncol, vol.34, pp.3375-3382, 2016. ,
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study, Br J Cancer, vol.110, pp.55-62, 2014. ,
, PMA P150047: FDA summary of safety and effectiveness data page 1 summary of safety and effectiveness data (SSED), US Food and Drug Administration, 2016.
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study, Ann Oncol, vol.26, pp.1883-189, 2015. ,
, US Food and Drug Administration. cobas EGFR Mutation Test v2, 2016.
A case of cancer in which cells similar to those in the tumours were seen in the blood after death, Aust. Med. J, vol.14, pp.146-147, 1869. ,
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing, Cancer Res, vol.73, pp.2965-2975, 2013. ,
RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis, Nature, vol.487, pp.510-513, 2012. ,
The dynamic range of circulating tumor DNA in metastatic breast cancer, Breast Cancer Res, vol.16, p.421, 2014. ,
Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients, Proc Natl Acad Sci U S A, vol.110, pp.21083-21088, 2013. ,
Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer, Nat Biotechnol, vol.32, pp.479-484, 2014. ,
Circulating tumor cells in patients with breast cancer dormancy, Clin Cancer Res, vol.10, pp.8152-8162, 2004. ,
Isolation of rare circulating tumour cells in cancer patients by microchip technology, Nature, vol.450, pp.1235-1239, 2007. ,
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases, Clin Cancer Res, vol.10, pp.6897-6904, 2004. ,
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay, Nat Biotechnol, vol.31, pp.539-544, 2013. ,
Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis, Cell, vol.158, pp.1110-1122, 2014. ,
Real-time imaging reveals the single steps of brain metastasis formation, Nat Med, vol.16, pp.116-122, 2010. ,
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer, Sci Transl Med, vol.2, pp.25-48, 2010. ,
Recent advances in the biology of human circulating tumour cells and metastasis, ESMO Open, vol.1, p.78, 2016. ,
Profiling protein expression in circulating tumour cells using microfluidic western blotting, Nature Communications, vol.8, p.14622, 2017. ,
Clinical Applications of Circulating Tumor Cells in Pharmacotherapy: Challenges and Perspectives, Molecular Pharmacology, vol.92, issue.3, pp.232-239, 2017. ,
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients, J. Natl Cancer Inst, vol.18, p.66, 2012. ,
Circulating tumor cells, disease progression, and survival in metastatic breast cancer, N. Engl. J. Med, vol.351, issue.8, pp.781-791, 2004. ,
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment, Breast Cancer Res, vol.13, 2011. ,
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients, J Natl Cancer Inst, vol.106, 2014. ,
The significant prognostic value of circulating tumor cells in triple-negative breast cancer: a meta-analysis, Oncotarget, 2016. ,
Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer, Breast Cancer, vol.23, issue.1, pp.120-127, 2016. ,
Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis, Clin. Transl. Oncol, vol.18, issue.3, pp.322-330, 2016. ,
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer, J Clin Oncol, vol.32, pp.1136-1142, 2014. ,
Circulating tumor cells predict survival benefi t from treatment in metastatic castration-resistant prostate cancer, Clin Cancer Res, vol.14, pp.6302-6311, 2008. ,
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data, Lancet Oncol, vol.10, pp.233-239, 2009. ,
Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications, Ann. Oncol, vol.19, issue.5, pp.891-897, 2008. ,
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer, Clin Cancer Res, vol.13, pp.7053-7058, 2007. ,
Circulating tumor cells predict survival in patients with metastatic prostate cancer, Urology, vol.65, issue.4, pp.713-718, 2005. ,
Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study), J Clin Oncol, p.5035, 2015. ,
Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer, J Clin Oncol, vol.30, pp.525-557, 2012. ,
Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer, Br. J. Cancer, vol.114, issue.2, pp.138-145, 2016. ,
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer, J. Clin. Oncol, vol.26, pp.3213-3221, 2008. ,
Evaluation and prognostic signifi cance of circulating tumor cells in patients with non-small-cell lung cancer, J Clin Oncol, vol.29, issue.12, pp.1556-63, 2011. ,
Circulating tumor cells identify early recurrence in patients with non-small-cell lung cancer undergoing radical resection, PLoS ONE, vol.11, issue.2, p.148659, 2016. ,
Evaluation of circulating tumor cells and circulating tumor DNA in non-small-cell lung cancer: association with clinical endpoints in a Phase II clinical trial of pertuzumab and erlotinib, Clin. Cancer Res, vol.18, issue.8, p.2391, 2012. ,
Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis, PLoS One, vol.8, p.78070, 2013. ,
Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges, Clin Lung Cancer, vol.17, pp.507-523, 2016. ,
Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer, Interact Cardiovasc Thorac Surg, vol.18, pp.775-83, 2014. ,
Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker, Clin Cancer Res, vol.17, pp.827-862, 2011. ,
Tumour cells in the tumour draining vein of patients with non-small cell lung cancer: detection rate and clinical significance, Eur J Cardiothorac Surg, vol.23, pp.451-457, 2003. ,
Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer, J. Clin. Oncol, vol.30, issue.5, pp.525-532, 2012. ,
Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell-lung cancer, Future Oncol, vol.12, issue.6, pp.789-799, 2016. ,
Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer, Int J Cancer, vol.135, pp.1978-1982, 2014. ,
Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma, Int J Cancer, vol.133, pp.2165-2171, 2013. ,
Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer, Ann Surg, vol.255, pp.1105-1112, 2012. ,
Detection of circulating tumor cells in advanced head and neck cancer using the CellSearch system, Head Neck, vol.34, pp.1440-1444, 2012. ,
Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis, Tumour Biol, vol.35, pp.2473-2480, 2014. ,
Circulating melanoma cells and survival in metastatic melanoma, Int J Oncol, vol.38, pp.755-760, 2011. ,
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study, Oncologist, vol.17, pp.947-955, 2012. ,
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents, Ann Oncol, vol.21, pp.1006-1012, 2010. ,
Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer, J. Oncol, p.617421, 2010. ,
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival, Clin Cancer Res, vol.12, pp.4218-4224, 2006. ,
Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer, Breast Cancer, vol.17, pp.199-204, 2010. ,
Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer, J Clin Oncol, vol.27, pp.5153-5159, 2009. ,
Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer, Clin Cancer Res, vol.12, pp.6403-6409, 2006. ,
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer, J Clin Oncol, vol.23, pp.1420-1430, 2005. ,
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience, Ann Oncol, vol.20, pp.27-33, 2009. ,
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer, J Clin Oncol, vol.27, pp.3742-3748, 2009. ,
Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges, Clin Chem, vol.57, pp.1242-1255, 2011. ,
Circulating tumor cells in breast cancer, Mol Oncol, vol.10, pp.418-430, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-00749450
High independent prognostic and predictive ,
Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression, Br J Cancer, vol.104, pp.464-468, 2011. ,
Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR, Clin Biochem, vol.48, pp.999-1002, 2015. ,
Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies, Clin Pharmacol Ther, vol.95, pp.24-31, 2014. ,
Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients, PLoS One, vol.9, p.85350, 2014. ,
Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses, Clin Cancer Res, vol.22, pp.1103-1113, 2016. ,
Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer, J Clin Oncol, vol.31, pp.2273-81, 2013. ,
Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients, Proc Natl Acad Sci, vol.110, pp.21083-21091, 2013. ,
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment, PLoS ONE, vol.9, p.103883, 2014. ,
Overcoming drug resistance to receptor tyrosine kinase inhibitors: learning from lung cancer, Pharmacol Ther, vol.161, pp.97-110, 2016. ,
Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients, Mol Oncol, vol.7, pp.976-986, 2013. ,
Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer: cotargeting signaling pathways, J Natl Cancer Inst, vol.107, p.10, 2015. ,
mutations: implications for targeted therapies in metastatic colorectal cancer, Lancet Oncol, vol.12, pp.594-603, 2011. ,
HER2 gene amplification can be acquired as breast cancer progresses, Proc Natl Acad Sci U S A, vol.101, pp.9393-9401, 2004. ,
Current and emerging therapies of HER2positive metastatic breast cancer, Breast, vol.29, pp.170-177, 2016. ,
HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact, Cancer Treat Rev, vol.39, pp.947-957, 2013. ,
Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": Trastuzumab in HER2/neu-positive breast carcinoma, J Cancer Res Clin Oncol, vol.137, pp.1317-1344, 2011. ,
CTCs and HER2-positive CTCs detection by CellSearch® in non-metastatic breast cancer: an international ring study to assess interreader variability, Cancer Res, vol.71, pp.4-07, 2011. ,
Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy, J Clin Oncol, vol.31, pp.1703-1709, 2013. ,
Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK19mRNA-positive circulating tumor cells: results of a randomized phase II study, Ann Oncol, vol.23, pp.1744-50, 2012. ,
Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer, Ann Oncol, vol.18, pp.1623-1631, 2007. ,
Circulating tumor cells: liquid biopsy of cancer, 2013. ,
, Clin Chem, vol.59, pp.110-118
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate, Eur Urol, vol.60, pp.897-904, 2011. ,
ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance, Clin Chem, vol.60, pp.1282-1289, 2014. ,
Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer, JAMA Oncol, vol.1, pp.582-591, 2015. ,
Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells, Eur Urol, vol.68, pp.939-945, 2015. ,
resistance to enzalutamide and abiraterone in prostate cancer, N Engl J Med, vol.371, pp.1028-1038 ,
Tracking genomic cancer evolution for precision medicine: The lung TRACERx study, PLoS Biol, vol.12, p.1001906, 2014. ,
The National Lung Matrix Trial: Translating the biology of stratification in advanced non-small-cell lung cancer, Ann. Oncol, vol.26, pp.2464-2469, 2015. ,
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer, Ann. Oncol, vol.26, pp.1408-1415, 2015. ,
Molecular profiling of single circulating tumor cells with diagnostic intention, EMBO Mol. Med, vol.6, pp.1371-1386, 2014. ,
Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients ,
, Oncol, vol.9, pp.850-860, 2015.
KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue, Int. J. Cancer, vol.133, pp.130-141, 2013. ,
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer, Cancer Discov, vol.2, pp.995-1003, 2012. ,
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition, Science, vol.339, pp.580-584, 2013. ,
Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells, PLoS One, vol.9, p.101777, 2014. ,
Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture, JAMA Otolaryngol. Head Neck Surg, vol.140, pp.1225-1236, 2014. ,
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations, N. Engl. J. Med, vol.367, pp.1694-1703, 2012. ,
,
, RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer, Nat Med, vol.21, issue.9, pp.1038-1085, 2015.
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer, Sci. Transl. Med, vol.8, pp.327-351, 2016. ,
Adaptive therapy, Cancer Res, vol.69, pp.4894-4903, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-01887358
Evolutionary approaches to prolong progression-free survival in breast cancer, Cancer Res, vol.72, pp.6362-70, 2012. ,
,
, Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to antiEGFR treatment, Ann Oncol, vol.26, pp.731-737, 2015.
Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor, Melanoma Res, vol.22, pp.466-72, 2012. ,
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance, Nature, vol.494, pp.251-256, 2013. ,
,
, Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Relling Science, vol.286, issue.5439, pp.487-491, 1999.
On the use of pharmacogenetics in cancer treatment and clinical trials ,
, Eur J Cancer, vol.50, issue.15, pp.2532-2575, 2014.
Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives, Pharmgenomics Pers Med, vol.9, pp.65-77, 2016. ,
Somatic pharmacogenomics in cancer, Pharmacogenomics J, 2008. ,
, , vol.8, pp.305-319
, Pharmacogenomics in oncology care. Front Genet, vol.5, p.73, 2014.
Biomarqueurs du cancer bronchique non à petites cellules : du concept à la pratique clinique, La Lettre du Cancérologue, pp.210-233, 2008. ,
, Intérêts des biomarqueurs biologiques dans les essais cliniques
, Université Henri Poincaré-Nancy, vol.1, 2011.
Pharmacogénétique des analogues nucléosidiques : Cytidine déaminase et issue clinique. Aix-Marseille Université. 25 septembre, 2015. ,
L'invention de la médecine personnalisée, Med Sci (Paris), vol.31, pp.797-803, 2015. ,
,
Cancer : comprendre la médecine personnalisée. Le Figaro Santé. 6 novembre, 2014. ,
, Les défis de l'immunothérapie en oncologie
Immunothérapies des cancers : rationnel et avancées récentes, Rev Med Interne, 2016. ,
, Biomarqueurs des immunothérapies anti-PD-1/PD-L1 : facteurs cliniques, histologiques et immunohistochimiques associés au statut PD-L1. Université Paris Descartes. 20 juin, 2016.
Effets secondaires des nouvelles thérapies ,
Immunothérapie anti-cancéreuse ,
, Immunothérapie : tirer parti de l'immunité, p.348
, Ose pharma, vol.29
Évaluation de l'acte de recherche ou de quantification du gène de fusion BCR-ABL par RT-PCR dans le diagnostic et le suivi thérapeutique des leucémies myéloïdes chroniques et des leucémies lymphoblastiques aiguës, 2017. ,
Biologie de la protéine de fusion BCR-ABL : progrès récents, Hématologie, vol.8, issue.1, pp.35-45, 2002. ,
Les Thérapies ciblées et leur place en onco-hématologie ,
, Partie II-Autres molécules informationnelles. Chapitre 8-Facteurs de croissance
Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia, Leukemia Research and Treatment, vol.2015 ,
Les Tests de Genetique Moléculaire Pour l'accès Aux Thérapies Ciblées en 2012, 2012. ,
, Les thérapies ciblées orales. Onconews numéro 10. Octobre 216
, Le prix des médicaments anticancéreux. Institut National du Cancer
Glivec®): une révolution dans le traitement de la leucémie myéloïde chronique (LMC). Médecine thérapeutique, vol.11, pp.428-436, 2005. ,
Implementing Genome-Driven Oncology, Cell, vol.168, issue.4, pp.584-599, 2009. ,
DOI : 10.1016/j.cell.2016.12.015
URL : http://europepmc.org/articles/pmc5463457?pdf=render
, , 2013.
Les inhibiteurs de tyrosine kinase de l'EGFR dans le traitement du CBNPC, N° 8-C2. Octobre, vol.24, pp.188-197, 2007. ,
Fonctionnalité de la signalisation en aval des récepteurs HER : Implication de la réponse cellulaire et tumorale aux thérapies ciblées, 2011. ,
EGFR Signaling in Colorectal Carcinoma, Pathology Research International, vol.2011 ,
,
Kras et cancer colorectal : un pas de géant vers la médecine personnalisée ,
, , vol.24, pp.196-209, 2009.
Traitement des progressions tumorales dans le cancer du poumon muté EGFR : à propos d'une cohorte de patients métastatiques suivis à l'Institut Bergonié, 2015. ,
Thérapeutiques ciblées « pour les nuls » : modes d'action des anti-EGFR et des anti-VEGF, Hepato Gastro, vol.18, pp.4-17, 2011. ,
Cancer colorectaux métastatiques et thérapies ciblées anti-EGFR, MEDECINE/SCIENCES, vol.25, issue.1, pp.13-20, 2009. ,
DOI : 10.1051/medsci/2009251s13
URL : https://www.medecinesciences.org/articles/medsci/pdf/2009/03/medsci2009251sp13.pdf
, Les inhibiteurs de tyrosine kinase de l'EGFR dans le CBNPC : sont-ils tous identiques ? La Lettre du Cancérologue ?, pp.6-2014
Cancers bronchiques non à petites cellules EGFR mutés, Revue des Maladies Respiratoires Actualités, vol.8, pp.373-381, 2016. ,
Colorectal cancer in the world: incidence, mortality and risk factors, Biomedical Research and Therapy, vol.4, issue.10, pp.1656-1675 ,
,
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev, vol.6, p.7047, 2017. ,
Epidemiologie-des-cancers/Les-cancers-les-plus-frequents/Cancer-colorectal ,
Clinical relevance of EGFR-and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR, Cancer Treatment Reviews, vol.35, issue.3, pp.262-271, 2009. ,
,
Les thérapies ciblées et leurs indications dans les tumeurs solides. La Revue de médecine interne, vol.30, pp.416-424, 2009. ,
Biomarqueurs prédictifs de réponse aux thérapies ciblées en oncologie, Ann Biol Clin, vol.71, issue.1, pp.89-97, 2013. ,
Biomarqueurs des cancers colorectaux utiles en pratique clinique, 2014. ,
Les indications et le maniement des anticorps anti-EGFR dans les cancers colorectaux, Hépato-Gastro, vol.15, 2008. ,
, Commission de la Transparence. Cétuximab. Avis 2 décembre, HAS, 2015.
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, vol.351, issue.4, pp.337-382, 2004. ,
, Commission de la Transparence. Cétuximab. Avis 16 mars, HAS, 2005.
Cétuximab (Erbitux®) dans le traitement du cancer colorectal métastatique ,
, La lettre de l'hépato-gastroentérologue-n° 2-vol. VIII-mars-avril, pp.81-82, 2005.
, Commission de la Transparence. Panitumumab. Avis 8 mars, HAS, 2017.
,
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer, N Engl J Med, vol.369, pp.1023-1057, 2013. ,
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer, J Cancer Res Clin Oncol, 2012. ,
, , vol.138, pp.65-72
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer, Clin Cancer Res, vol.21, issue.24, pp.5469-79, 2015. ,
, Commission de la Transparence. Panitumumab. Avis 8 avril, HAS, 2008.
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer, J Clin Oncol, vol.25, issue.13, pp.1658-64, 2007. ,
, IFCT. Biomarqueurs et cancers du poumon : l'IFCT
, Cancérologie Thoracique) et Roche travaillent ensemble pour offrir plus de chances aux malades, 2010.
Precision medicine in oncology drug development: a pharma perspective, Drug Discov Today, vol.20, issue.12, pp.1455-63, 2015. ,
LUNG CANCER FACT SHEET. ASLC Highlights Promising Advances. 30 novembre, 2015. ,
, Lung Cancer Europe. LuCE Report on lung cancer, 2016.
, Séries Guide pour les Patients ESMO. Cancer du poumon non à petites cellules
, Rapport d'orientation. Pertinence du dépistage du cancer broncho-pulmonaire en, HAS
Point de situation sur les données disponibles. Analyse critique des études contrôlées randomisées, 2016. ,
, Mutations de l'EGFR dans le cancer du poumon : mise en évidence d'une cible moléculaire permettant un accès spécifique aux thérapies ciblées, 2010.
Place des thérapies ciblées dans la prise en charge du Cancer Bronchique Non à Petites Cellules (CBNPC), 2016. ,
, Tumeurs du poumon, primitives et secondaires, Pneumologie. Item, vol.306, 2017.
, Globocan. « www.iacr.com
Rapport technique. Projection de l'incidence et de la mortalité par cancer en France métropolitaine en 2017, 2017. ,
, Cancer bronchique non à petites cellules / Référentiel national de RCP. Version interactive. Décembre, 2014.
La place des inhibiteurs des tyrosine kinases de l'EGFR dans les cancers bronchiques non à petites cellules avancés, La Lettre du Cancérologue ?, pp.10-2011 ,
Test compagnon associé à une thérapie ciblée : définitions et méthode d'évaluation. Février, 2014. ,
, Les Thérapies Ciblées les plus utilisées dans les Traitements AntiCancéreux. ICM. 14 octobre, 2014.
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS), J Clin Oncol, vol.29, pp.2866-2874, 2011. ,
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Eng J Med, vol.362, issue.25, pp.2380-2388, 2010. ,
Gefitinib versus cisplatin plus docetaxel in patients with nonsmall-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, vol.11, issue.2, pp.121-128, 2010. ,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, 2009. ,
, N Eng J Med, vol.361, issue.10, pp.947-957
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC), Lancet Oncol, vol.13, issue.3, pp.239-246, 2012. ,
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG0802): a multi-centre, open-label, randomised, phase 3 study, Lancet Oncol, vol.12, issue.8, pp.735-742, 2011. ,
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, vol.31, 2013. ,
, Les nouvelles cibles thérapeutiques. Les nouvelles thérapeutiques ciblées. Cancer du sein: Compte-rendu du cours supérieur francophone de cancérologie, pp.233-266
Chimiothérapie orale et soins de support : Enquête sur les besoins des pharmaciens d'officine. Création du lien ville-hôpital, 2016. ,
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non-Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.22, pp.3238-3247, 2004. ,
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis, J Cell Mol Med, vol.14, issue.1-2, pp.51-69, 2010. ,
Intérêt des biomarqueurs pour prédire l'efficacité des inhibiteurs de tyrosine kinase anti-EGFR, données du projet ERMETIC, La Lettre du Pneumologue ? ,
, XIII-n° 2-mars-avril 2010, pp.66-67
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, The Lancet Oncology, vol.11, issue.6, pp.70112-70113, 2010. ,
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial, Clin Cancer Res, vol.20, issue.7, pp.2001-2011, 2014. ,
, Communication directe aux Professionnels de la santé, Tarceva®
, Commission de la transparence, HAS
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial, J Clin Oncol, vol.28, issue.5, pp.744-52, 2010. ,
L'afatinib, un inhibiteur de la famille ErbB Données pratiques d'utilisation dans le traitement du cancer bronchique non à petites cellules, Bulletin Infirmier du Cancer, vol.14, pp.42-46 ,
, Commission de la Transparence. Afatinib. 25 mai, HAS, 2016.
, Synthèse d'avis de la Commission de la Transparence, Afatinib. Février, 2014.
, Commission de la Transparence. Osimertinib. 13 septembre, HAS, 2017.
, Commission de la Transparence. Osimertinib. 21 septembre, HAS, 2016.
, Synthèse d'avis de la commission de la Transparence, HAS
Illuminating ideas : Innovative clinical trial design ,
,
Les essais cliniques en oncologie, Bulletin Infirmier du Cancer ,
Conduite des essais cliniques de médicaments en onco/hématologie ciblés, guidés par la génomique, 2014. ,
Genomic Alteration-Driven Clinical Trial Designs in Oncology, Ann Intern Med, vol.165, issue.4, pp.270-278, 2016. ,
Particularité de la recherche clinique en cancérologie ,
Méthodologie des essais cliniques en cancérologie, La Lettre du Pharmacologue, vol.22 ,
Combined integrated protocol/basket trial design for a first-inhuman trial, Orphanet J Rare Dis, vol.11, issue.1, p.134, 2016. ,
, Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer. Am Soc Clin Oncol Educ Book, vol.2015
Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines, Statistics in Medicine, pp.1843-1861, 2017. ,
New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response, Eur Respir Rev, vol.23, issue.133, pp.367-78, 2014. ,
An efficient basket trial design, Stat Med, vol.36, issue.10, pp.1568-1579, 2017. ,
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples, Ann Oncol, vol.28, issue.1, pp.34-43, 2017. ,
Novel Precision Medicine Trial Designs: Umbrellas and Baskets, JAMA ,
, Oncol, vol.3, issue.3, p.423, 2017.
Core Concept: Basket trial approach capitalizes on the molecular mechanisms of tumors, Proc Natl Acad Sci, vol.113, issue.26, pp.7007-7008, 2016. ,
The Bayesian basket design for genomic variant-driven phase II trials ,
, Semin Oncol, vol.43, issue.1, pp.13-18, 2016.
Basket trials and the evolution of clinical trial design in an era of genomic medicine, J Clin Oncol, vol.33, issue.9, pp.975-982, 2015. ,
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity, Mol Oncol, vol.9, issue.5, pp.967-96, 2015. ,
Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker, Clin Pharmacol Ther, vol.100, issue.6, pp.617-625, 2016. ,
Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study, Statistics in Biopharmaceutical Research, vol.8, pp.2016-2019 ,
Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology, Annu Rev Med, vol.69, pp.319-331, 2018. ,
, Basket study': Clinical trial design explores responses to drugs based on specific mutations in patients' tumors
, , 2015.
Clinical Trial Shows Promise of "Basket Studies" for Cancer Drugs ,
, Memorial Sloan Kettering Cancer Center, 2015.
Les essais cliniques en cancérologie : spécificités, structures et financements. DIU Chef de Projet / infirmiers & techniciens en recherche clinique. Institut National du Cancer. Département de Recherche Clinique, vol.13 ,
Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive malignancies in adults and children : feasability of the French National AcSé Program, 2014. ,
Biomarker-driven access to crizotinib in ALK, MET, or ROS1 positive (+) malignancies in adults and children: The French National AcSé Program, Journal of Clinical Oncology, vol.36, pp.15-2504, 2018. ,
, Final results of the Acsé-crizotinib national programme : Demonstration of equal and safe access to a targeted therapy beyond its initial indications. Higlights. Gustave Roussy at ASCO, 2018.
, Commission de la Transparence, HAS
VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: first results of the ACSE trial, Annals of Oncology, vol.27, 2016. ,
, Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acsé Phase II Trial, vol.130, p.156, 2018.
Biomarker-driven access to vemurafenib in BRAF-positive cancers: Second study of the French National AcSé Program, Journal of Clinical Oncology, vol.34, pp.11620-11620, 2016. ,
P3.02a-034 Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSé Trial, Journal of Thoracic Oncology, vol.12, issue.1, pp.1182-1183 ,
Rôle de l'INCa dans le soutien de la recherche et des groupes coopérateurs. Institut National du Cancer, Symposium « Immunopathologie et cancers ». 27 mars, 2018. ,
, , 2017.
Nouvelles approches des essais thérapeutiques à l'heure de la médecine personnalisée ,
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations, N Engl J Med, vol.373, pp.726-762, 2015. ,
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis, JAMA Oncology, vol.4, issue.3, 2017. ,
VE-BASKET, a first-in-kind, phase II, histologyindependent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m), Journal of Clinical Oncology, vol.32, pp.2533-2533, 2014. ,
Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the ,
, Blood, vol.128, issue.22, p.480, 2018.
, FDA Announces First Approval of Targeted Therapy Based on Basket Study. Memorial Sloan Kettering Cancer Center, 2017.
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. Ann Oncol, vol.28, pp.3000-3008, 2017. ,
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'. Ann Oncol, vol.29, pp.758-765, 2018. ,
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE', Eur J Cancer, vol.94, pp.156-167, 2018. ,
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial, Lancet Respir Med, 2018. ,
, , vol.6, pp.30116-30120
Crizotinib achieves objective responses and long-lasting disease control in patients with metastatic papillary renal cell carcinoma type 1 (pRCC1) with somatic MET mutations. EORTC phase II trial 90101 'CREATE, AACR Annual Meeting, 2016. ,
, , 2016.
STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions, Supplement), vol.060, issue.77, 2017. ,
Ignyta Announces Results for Potential New Cancer Treatment, 2016. ,
Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements, Presented at the 2016 AACR Annual Meeting ,
, Ignyta's-Entrectinib-Suggests-Potential-Best-in-Class
Potential Seen for Entrectinib for Specific Patients With Sarcoma Harboring Genetic Rearrangements. Targeted Oncology, 2017. ,
Poster 080 #2798661 Preliminary evidence of clinical response to entrectinib in three sarcoma patients, CTOS Annual Meeting, 2017. ,
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors, Ther Clin Risk Manag, vol.14, pp.1247-1252, 2018. ,
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, N Engl J Med, vol.344, p.783, 2001. ,
,
HER kinase inhibition in patients with HER2-and HER3-mutant cancers, Nature, vol.554, issue.7691, pp.189-194, 2018. ,
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a nonrandomised, open-label, phase 1b trial, Lancet Oncol, vol.18, issue.5, pp.623-630, 2017. ,
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal, Ann Oncol, vol.28, issue.5, pp.1036-1041, 2017. ,
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study, J Clin Oncol, vol.35, issue.36, pp.4050-4056, 2017. ,
Pembrolizumab for patients with PD-L1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study, Annals of Oncology, vol.28, 2017. ,
ATIM-35. Results of the phase IB KEYNOTE-028 multi-cohort trial of pembrolizumab monotherapy in patients with recurrent PD-L1-positive glioblastoma multiforme (GBM), Neuro-Oncology, vol.18, pp.25-26, 2016. ,
Pembrolizumab in patients (pts) with PD-L1-positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028, Journal of Clinical Oncology, vol.35, pp.5513-5513, 2017. ,
525 POSTER : Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028, European Journal of Cancer, vol.51, 2015. ,
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study, J Clin Oncol, vol.35, issue.34, pp.3823-3829, 2017. ,
Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma, J Clin Oncol, vol.36, issue.1, pp.61-67, 2018. ,
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial, J Clin Oncol, vol.35, issue.36, pp.4035-4041, 2017. ,
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One, vol.12, p.189848, 2017. ,
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study, Am J Clin Oncol, 2018. ,
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer, Clin Cancer Res, vol.24, issue.12, pp.2804-2811, 2018. ,
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 ,
, , vol.35, pp.2535-2541, 2017.
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study, Ann Oncol, vol.29, issue.8, pp.1807-1813, 2018. ,
Pembrolizumab in MSI-H or dMMR Solid Tumors ,
, Tissue/Site-Agnostic' Approval by FDA. The Asco post, 2018.
Signature program: a platform of basket trials, Oncotarget, vol.9, pp.21383-21395, 2018. ,
The Signature Program: Bringing the Protocol to the Patient, Clin Pharmacol Ther, vol.98, issue.2, pp.124-126, 2015. ,
Novel Trial Program Puts Patients First, Targeted Oncology, 2015. ,
Signature Trial Program Aims for Rapid Delivery of Novel Therapies ,
, , vol.17, 2016.
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children, N Engl J Med, vol.378, issue.8, pp.731-739, 2018. ,
Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers, J Hematol Oncol, vol.11, p.78, 2018. ,
New Designs for Basket Clinical Trials in Oncology, Journal of Biopharmaceutical Statistics, 2017. ,
New Oncology Clinical Trial Designs: What Works and What Doesn't? Evidence-Based Oncology, The American Society of Clinical Oncology Annual Meeting, 2015. ,
Basket Study" May Open Doors for, Clinical Trials for Mesothelioma Patients. Mesothelioma Counsel. Posted on Thursday, 2015. ,
Basket Trials" Mark An Exciting New Era In Cancer Research and Treatment. Formerly of Roswell Park Comprehensive Cancer Center, Tuesday, 2015. ,
Basket Studies: The Next Frontier In Breast Cancer Research. Breast Health, 2015. ,
Memorial Sloan Kettering Cancer Center Announces Innovative Basket Study. The Life Raft Group, 2015. ,
Patient-centric trials for therapeutic development in precision oncology, Nature, vol.526, issue.7573, pp.361-70, 2015. ,